Volume : 11, Issue : 07, July – 2024
Title:
A REVIEW ON RISK MANAGEMENT OF PHARMACEUTICAL PRODUCT AND PHARMACEUTICAL TOXICOLOGY
Authors :
Lavanya J M*, Shibina S, Aparna P, Prasobh G.R
Abstract :
Risk management in the pharmaceutical industry is a critical process that ensures the safety, efficacy, and quality of pharmaceutical products. This discipline involves identifying, assessing, and mitigating risks throughout the lifecycle of a drug, from development to post-market surveillance. Key strategies include rigorous clinical testing, thorough regulatory compliance, and continuous monitoring of adverse events. Pharmaceutical toxicology, a vital component of risk management, focuses on the study of adverse effects of chemical substances on living organisms. It provides essential data that help predict potential toxicities and guide the safe development of new drugs. Toxicological assessments are performed through various in vitro and in vivo studies, providing insights into the mechanisms of toxicity, dose-response relationships, and potential human health impacts. Effective integration of risk management and toxicological evaluation is crucial for minimizing risks and ensuring patient safety.
Keywords: Mitigating, Toxicological, dose-response relationships, clinical testing, Regulatory compliance.
Cite This Article:
Please cite this article in press Lavanya J M et al A Review On Risk Management Of Pharmaceutical Product And Pharmaceutical Toxicology.,Indo Am. J. P. Sci, 2024; 11 (07).
Number of Downloads : 10
References:
1. Reddy VV, Vishal Gupta N, Raghunandan HV, Nitin Kashyap U. Quality risk management in pharmaceutical industry: A review. International Journal of Pharm Tech Research. 2014; 6(3):908-14.
2. Near JC. Quality Management Systems and Risk Management. In Good Manufacturing Practices for Pharmaceuticals, Seventh Edition 2019 Feb 4 (pp. 19-31). CRC Press.
3. Mandhare TA, Khuspe PR, Nangare PS, Vyavhare RD. Quality Risk Management: A Review. American Journal of PharmTech Research. 2018; 8(2):56-86.
4. Sodhi MS, Tang CS. Managing supply chain risk. New York: Springer; 2012 Feb 25.
5. Viornery L, Le Goff P. Quality Risk Management. Implementation of Q9 in Pharmaceutical field an example of methodology from PIC/S. Pharmaceutical Inspection Cooperation Scheme. 2010 Jan 4:1-30. 10.
6. Lu Z, Su J. Clinical data management: Current status, challenges, and future directions from industry perspectives. Open Access Journal of Clinical Trials. 2010 Jun 22:93-105.
7. Dg A. The revised consort statement for reporting randomized trials: Explanation and elaboration. JAMA.
8. Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. Asian Journal of Pharmaceutical Research and Health Care. 2010:127-34. 2001; 134:663-94.
9. Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. Chapman and hall/CRC; 2017 Aug 15.
10. Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. Asian Journal of Pharmaceutical Research and Health Care. 2010:127-34.
11. Lee B, Turner WM. Food and Drug Administration’s adverse drug reaction monitoring program. American Journal of Health-System Pharmacy. 1978 Aug 1; 35(8):929-932.
12. Tralau T, Oelgeschläger M, Gürtler R, Heinemeyer G, Herzler M, Höfer T, Itter H, Kuhl T, Lange N, Lorenz N, Müller-Graf C. Regulatory toxicology in the twenty-first century: challenges, perspectives and possible solutions. Archives of Toxicology. 2015 Jun; 89:823-50.